Carthera, a Paris, France-based clinical-stage medtech company, raised additional €4.5M in funding.
The round, which brought the total amount of Series B to €42M, saw participation from Unorthodox Ventures, with participation from Supernova Invest, Saint-Genys and Bouscas Med.
Founded in 2010 by Pr. Alexandre Carpentier, run by CEO Frederic Sottilini, and chaired by Oern Stuge MD, Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of brain disorders. The company, a spin-off from AP-HP Paris and Sorbonne University, leverages the inventions of Pr. Alexandre Carpentier, head neurosurgeon at AP-HP Sorbonne university, who has achieved worldwide recognition for his innovative developments in treating brain disorders. Carthera is developing SonoCloud®, an intracranial implant that temporarily opens the Blood-Brain Barrier (BBB). The device is currently in clinical trials in Europe and the United States.
The funding will support the company in launching its first registrational trial using its SonoCloud technology in the treatment of recurrent glioblastoma (rGBM). The study will be an international, multicenter, two-arm clinical trial randomized with a 1:1 ratio. The open-label, comparative pivotal trial will evaluate overall survival in patients undergoing carboplatin chemotherapy and treated with the SonoCloud-9® system to open the Blood Brain Barrier (BBB). This will be compared to the standard of care (lomustine and temozolomide) in patients with first recurrence of GBM.
In parallel to the clinical trial, the funds will be used to develop the company’s clinical and preclinical pipeline in the field of neurodegenerative diseases. Carthera is actively seeking to establish new research and clinical stage collaborations with pharmaceutical and biotech partners interested in using its SonoCloud technology to deliver their therapies to the brain.
Carthera has offices in France (Lyon and Paris) and a subsidiary in Boston, Massachusetts, USA.
FinSMEs
11/12/2023